

1 A Simple RT-PCR Melting temperature Assay to Rapidly Screen for Widely Circulating SARS-CoV-2
2 Variants.

3

4 Padmapriya Banada^a, Raquel Green^a, Sukalyani Banik^a, Abby Chopoorian^a, Deanna Streck^b, Robert Jones^c,
5 Soumitesh Chakravorty^{a,d} and David Alland^a

6 ^aPublic Health Research Institute; Center for Emerging Pathogens, Rutgers New Jersey Medical School;

7 ^bInstitute of Genomic Medicine, Rutgers New Jersey Medical School, Newark, NJ; ^cCraic Computing LLC,

8 Snohomish, WA ; ^dCepheid, Sunnyvale, CA.

9 Running Head: SARS-CoV-2 variant strain detection

10 Key words: SARS-CoV-2, Variants, N501Y, E484K, melting temperature (T_m), screening test.

11

12

13 **Abstract.**

14 **Background.** The increased transmission of SARS-CoV-2 variants of concern (VOC) which originated in
15 the United Kingdom (B.1.1.7), South Africa (B1.351), Brazil (P.1) and in United States (B.1.427/429)
16 requires a vigorous public health response, including real time strain surveillance on a global scale.
17 Although genome sequencing is the gold standard for identifying these VOCs, it is time consuming and
18 expensive. Here, we describe a simple, rapid and high-throughput reverse-transcriptase PCR (RT-PCR)
19 melting temperature (T_m) screening assay that identifies these three major VOCs. **Methods.** RT-PCR
20 primers and four sloppy molecular beacon (SMB) probes were designed to amplify and detect the SARS-
21 CoV-2 N501Y (A23063T) and E484K (G23012A) mutations and their corresponding wild type sequences.
22 After RT-PCR, the VOCs were identified by a characteristic T_m of each SMB. Assay optimization and
23 testing was performed with RNA from SARS-CoV-2 USA WA1/2020 (WT), a B.1.17 and a B.1.351 variant
24 strains. The assay was then validated using clinical samples. **Results.** The limit of detection (LOD) for both
25 the WT and variants was 4 and 10 genomic copies/reaction for the 501 and 484 codon assays, respectively.
26 The assay was 100% sensitive and 100% specific for identifying the N501Y and E484K mutations in
27 cultured virus and in clinical samples as confirmed by Sanger sequencing. **Conclusion.** We have developed
28 an RT-PCR melt screening test for the three major VOCs which can be used to rapidly screen large numbers
29 of patient samples providing an early warning for the emergence of these variants and a simple way to track
30 their spread.

31

32 **Introduction.**

33 In December 2020, public health officials in the United Kingdom observed a surge of COVID-19 cases in
34 Kent, England that appeared to be largely due to a specific variant of SARS-CoV-2 (1, 2). The new variant
35 was named Variant of Concern (VOC 202012/1) or B.1.1.7 based on its phylogenetic lineage. Early reports
36 suggested that B.1.1.7 was more transmissible and possibly more virulent than previous SARS-CoV-2
37 strains (3, 4), although the evidence did not suggest that B.1.1.7 caused a decrease in vaccine efficacy (5-
38 8). The B.1.1.7 variant has a number of mutations in the spike protein including single nucleotide
39 polymorphisms (SNPs) resulting in N501Y, A570D, D614G and P681H mutations, and deletions at amino
40 acids 69-70 and 144Y (6, 9). The N501Y (A23063T) mutation has been identified as an important
41 contributor to the worrisome phenotype (2, 4, 10, 11). Other SARS-CoV-2 strain variants have been
42 implicated in large outbreaks in South Africa (known as 20H/501Y.V2 or B.1.351 lineage) and Brazil
43 (20J/501Y.V3 or P.1 lineage) (12). These variants appear to have decreased the efficiency of some COVID-
44 19 vaccines (2, 13, 14). All three, B.1.1.7, B.1.351 and P.1 variants contain the N501Y mutation, while the
45 South African and Brazilian variants additionally contain mutations in E484K and K417N (1, 12). Thus,
46 the N501Y mutation appears to be an excellent marker for all three strains while the E484K mutation can
47 be used to differentiate the other two strains from B.1.1.7. New SARS-CoV-2 variants have also been
48 recently reported in the United States (5, 15). Most of the new variants also have mutations at the 501 and/or
49 484 position, although additional mutations such L452R have also been reported (15); however, the
50 epidemiological and clinical relevance of these new variants are still not well understood.

51 All three of the major SARS-CoV-2 N501Y variants are circulating around the world (1). However, the
52 distribution, extent, and spread of these variants are poorly understood in countries such as the United States
53 where only a small fraction (0.04 to 3.5%) of COVID-19 cases are analyzed by viral genomic sequencing
54 as per the CDC's national genomic surveillance dashboard (16). Viral genome sequencing is currently the
55 only method available to reliably detect rapidly emerging SARS-CoV-2 variants. Genomic sequencing has
56 the advantage of providing a detailed map of new mutations, which supports new variant discovery as well

57 as monitoring the exact type of the variant. However, genomic sequencing is expensive and difficult to
58 perform in real time. In contrast, RT-PCR testing for SARS-CoV-2 has become widespread. This diagnostic
59 approach is easy to perform in a high throughput manner, and rapid turnaround times are possible. However,
60 routine RT-PCR tests do not differentiate among SARS-CoV-2 variants, or do so only by producing
61 negative assay results (17), which still require sequence confirmation (18). Furthermore, the potential for
62 additional mutations to appear near key variant-defining alleles may complicate the development of RT-
63 PCR assays for SARS-CoV-2 variants (19). We have previously demonstrated that sloppy molecular
64 beacons (SMBs) combined with melting temperature (T_m) code analysis may be used to specifically detect
65 mutations in short genomic regions where a variety of mutations can exist (20).

66 Here, we apply this same T_m -based approach to detect and differentiate variant strains of SARS-CoV-2
67 with high sensitivity and specificity. This approach is flexible and can be used in high throughput manner,
68 easily allowing the addition of new mutation detecting assays as needed to identify and track new SARS-
69 CoV-2 variants as they emerge. Furthermore, this approach can be performed on a wide range of real-time
70 PCR instrumentation as long as they have the capacity to run melt curve analysis. The wide availability of
71 such instruments can allow quick adoption of this assay around the world, increasing access to real-time
72 monitoring of SARS-CoV-2 variant spread.

73 **Methods.**

74 **Ethical considerations.** The use of de-identified clinical samples from confirmed COVID-19 positive and
75 negative patients for PCR testing and sequencing was approved by the Rutgers Institutional Review Board
76 under protocol numbers 20170001218 and 2020001541.

77 **Viral cultures and RNA.** Genomic RNA from SARS-CoV-2 USA WA1/2020 (wild type, WT), viral
78 culture stocks of SARS-CoV-2 hCoV-19/England/204820464/2020 (B.1.1.7 variant, 501-MT) and SARS-
79 CoV-2 Isolate hCoV-19/South Africa/KRISP-K005325/2020 (B.1.351 variant, 484-MT) were obtained

80 from BEI Resources, NIAID (Manassas, VA). RNA was isolated from both the variant strains in a BSL3
81 laboratory, using RNAdvance viral RNA extraction kit (Beckman Coulter, Indianapolis, IN).

82 **Genome sequence analysis for assay design.** For initial analysis of the mutations in SARS-CoV-2, a total
83 of 330,132 high quality viral genome sequences deposited in GISAID (21) as of Jan 12, 2021, were
84 analyzed. Publicly available datasets were analyzed in this study. This data can be found here:
85 <https://www.gisaid.org/>. A 250-nucleotide region around the N501Y (A23063T) and E484K (G23012A)
86 positions in the reference strain (GenBank accession number MN908947) was selected and used to identify
87 the corresponding regions in the GISAID dataset using BLAST (22). These matching sequences were
88 condensed into a set of unique sequences and aligned using a multiple sequence alignment program,
89 MAFFT (23). Candidate amplification primers and probes were identified on the basis of sequence
90 conservation and predicted T_m using the algorithm of SantaLucia (24) and final set of primers were
91 designed with the help of the Primer3 program (25). SMB probe design was performed using the web
92 servers DNA mfold (<http://www.unafold.org/mfold/applications/dna-folding-form.php>) and DINAmelt
93 (<http://www.unafold.org/hybrid2.php>) to predict the probe folding structures and probe-target hybrid T_m
94 values respectively.

95 **Primers and Probes.** The list of primers and probes used for the 501 variant (SMB-501) and the 484 variant
96 (SMB-484) assays are shown in Table 1. Both assays were run as two separate reactions. For the SMB-501
97 assay an 89 bp region surrounding the 23063 position was amplified using an asymmetric PCR. For SMB-
98 484 assay, a 76bp region surrounding the 23012 position was amplified using an asymmetric PCR. Sloppy
99 molecular beacons (SMB) were designed targeting both the wild type 501N/484E (23063A/23012A) and
100 the mutant 501Y/484K (23063T/23012G) sequences (SMB-501-MT). Primers were obtained from
101 Millipore Sigma (The Woodlands, TX) and SMBs were synthesized by LGC Biosearch technologies
102 (Petaluma, CA). An internal control (IC) assay developed by CDC (26, 27), targeting the human RNaseP
103 gene was simultaneously performed for each extracted RNA specimen as a separate reaction in a separate

104 well, using the *TaqMan* real-time PCR assay probe tagged with FAM at the 5' end and Dabcyl quencher at
105 the 3' end.

106 **SMB-assay formulation and procedure.** TaqPath™ 1-Step RT-qPCR Master Mix, CG (ThermoFisher
107 Scientific, Waltham, MA) was used for the RT-PCR. Each one step reaction mix was supplemented with
108 0.2µM of the forward primer 501-F/484-F and 2 µM/4 µM of the reverse primer 501-R/484-R, 0.4 µM of
109 each of the SMB probes (SMB-501-WT and SMB-501-MT/ SMB-484-WT and SMB-484-MT) and 1 µl of
110 the template RNA (note that the concentration of the forward primers did not match the concentration of
111 the reverse primers so as to create an asymmetric PCR) . The internal control contained primers and a probe
112 specific for human RNaseP as described previously (26, 27). Each reaction was run in replicates of 4 in
113 384-well plates in a Roche LightCycler 480 (Roche, Indianapolis, IN). The one-step RT-PCR amplification
114 was performed with the following thermocycling conditions: Uracil DNA glucosylase incubation for 2 min
115 at 37°C and reverse transcription (RT) for 15 min at 50°C, followed by asymmetric PCR for 45 cycles
116 (denaturation at 95 °C for 1 s, annealing/extension at 55°C for 30 s). The post-PCR melt was performed
117 with the following conditions: denaturation at 95°C for 30s followed by cooling down to 45°C and gradual
118 heating to 85°C, with continuous monitoring of fluorescence at the rate of 2 acquisitions per °C. The total
119 assay time was 1h 17min. Automated T_m calls were performed by the LC480 T_m detection software at the
120 end of the PCR. The resulting T_m for each probe was identified and matched with the T_m-signature code
121 defined for the wildtype or the mutant variants.

122 **Analytical sensitivity.** The pre-quantitated genomic RNA from the SARS-CoV-2 USA WA1/2020 (WT)
123 obtained from BEI resources with the stock concentration of 1.8 x10⁴ genomic equivalents (GE)/µl was
124 diluted in Tris-EDTA (TE) buffer. A 1 µl of each concentration (400, 200, 40, 20 and 4 GE/µl for 501 assay
125 and 1000, 500, 100, 50 and 10 for 484 assay) was added to the one-step RT-PCR mix containing the primers
126 and probes and was evaluated in the SMB-501 assay or the SMB-484 assay. The RNA extracted from both
127 variant strains was quantified against a standard curve generated with the N1 gene-specific real time RT-
128 PCR assay (26, 27) and the concentration was determined to be 4x10⁵ GE/µl for B.1.17 and 7x10⁶ GE/µl

129 for B.1.351 variant strain. The mutant RNA was also serially diluted and 1 µl of each concentration
130 mentioned above was evaluated in both the assays.

131 **Validation with patient samples.** Deidentified nasopharyngeal (NP) swabs obtained from patients
132 undergoing routine COVID-19 clinical testing using the Xpert Xpress SARS-CoV-2 or Xpert Xpress
133 SARS-CoV-2/Flu/RSV (4-plex) test (Cepheid, Sunnyvale CA) assay in the CLIA and CAP certified
134 laboratory at the Public Health Research Institute (PHRI), Newark, NJ, were selected for this study. NP
135 swabs were collected in 3ml viral transport media (VTM) from Hardy diagnostics (Santa Maria, CA) or
136 Labscoop (Little Rock, AR) and were banked at either refrigerated conditions (for specimens first tested
137 within the previous 2 weeks) or frozen (for specimens stored longer than 2 weeks). The samples consisted
138 of 46 randomly selected COVID-19 positive samples of unknown genotype and a RT-PCR cycle threshold
139 (Ct) <42 with either Xpert Xpress SARS-CoV-2 or Xpert Xpress CoV-2/Flu/RSV test. Nine of the samples
140 had been banked between October 2020 through December 31, 2020, 16 in the month of January 2021, 15
141 in February 2021 and 6 in March 2021. Thirty COVID-19 negative specimens were randomly selected from
142 samples banked between Oct 2020 through Feb 2021. RNA was extracted from each specimen using a
143 QiaAmp viral RNA isolation kit, following the manufacturer's instructions (Qiagen, Valencia, CA) in a
144 BSL2 laboratory. A 5µl volume of RNA was added to the one-step RT-PCR mix containing the primers
145 and probes. A subset of these clinical samples consisting of 26/46 of the COVID-19 positive samples and
146 19/30 of the COVID-19 negative samples were using the SMB-484 assay, mainly based on the continued
147 availability of the sample for testing. The SMB-501, SMB-484 and the IC assays were tested in separate
148 wells in replicates of two. The samples that failed the IC assay were repeated starting with the RNA
149 extraction. A subset of samples that tested positive either for 501N/484E wildtype or 501Y/484K mutant
150 was confirmed by Sanger sequencing using the primer pair: F-5'ctatcaggccggtagcacac3' and R-
151 5'ctttcttttgaacttctacatg3' which amplifies a 143bp segment of the S-gene inclusive of the amino acid
152 positions at 484 and 501. Sequencing chromatograms were analyzed using Ugene (ver 37) comparing
153 against the known WT and MT sequences using MegAlign Pro software (DNASar, ver16).

154 **Statistical analysis.** Standard statistical analyses (average, standard deviation) and graphing were
155 performed using Microsoft excel (ver 2102) and GraphPad Prism 8.4.3 for Windows.

156 **Results.**

157 **Limit of detection.** The one-step RT mix containing asymmetric PCR primers and both wildtype and MT
158 specific probes was added with either WT RNA or MT RNA at different concentrations ranging from 400
159 to 4 GE/reaction (N=4) for SMB-501 assay and from 1000 to 10 GE/reaction for SMB-484 assay. After T_m
160 analysis was performed the T_m peak heights were highest in the assays with the largest added number of
161 GE and the peak heights progressively decreased as the number of GEs present in the reactions decreased.
162 However, T_m peak heights produced by both SMB 501-WT/ SMB 484-WT and SMB 501-MT/ SMB 484-
163 MT could still be reproducibly detected at the lowest concentration tested (4 or 10 GE/reaction) when tested
164 against both WT and N501Y mutant strains, defining the assay limit of detection as ≤ 4 GE per reaction for
165 SMB-501 or ≤ 10 GE/reaction for SMB-484 assay (Fig. 1).

166 **T_m code definition.** The T_m values produced by both SMBs against the reference WT and the MT SARS-
167 CoV-2 strains are listed in Table 2. The mean and standard deviations shown were derived from at least 4
168 replicates. When reference RNA was tested with the SMB 501-WT probe, WT-RNA produced a T_m of
169 $59.8 \pm 0.4^\circ\text{C}$ and MT N501Y RNA produced a T_m of $55.2 \pm 0.4^\circ\text{C}$. Similarly, when RNA was tested with the
170 SMB 501-MT probe, WT-RNA produced a T_m of $58.2 \pm 1^\circ\text{C}$, and MT N501Y RNA produced a T_m of
171 $62.25 \pm 0.6^\circ\text{C}$. Given that T_m values can vary slightly between clinical samples, we specified a two-
172 temperature T_m code that identified either 501N or 501Y alleles within a T_m range of approximately 1.5-
173 4 times the experimentally verified \pm SD values for each probe T_m. Thus, the 501N (WT) T_m code was
174 defined as a SMB-501-WT T_m of $59.8 \pm 1.5^\circ\text{C}$ and a SMB-501-MT T_m of $58.2 \pm 1.5^\circ\text{C}$; and a 501Y (MT)
175 T_m code was defined as a SMB-501-WT T_m of $55.2 \pm 1.5^\circ\text{C}$ and a SMB-501-MT T_m of $62.25 \pm 1.5^\circ\text{C}$.
176 Similarly, for SMB-484 assay, the reference T_m code for 484E (WT) was 64 ± 0.1 (with SMB-484-WT
177 probe) and 58.7 ± 0.4 (with SMB-484-MT probe); and the reference T_m code for 484K (MT) was 59.7 ± 0.5
178 (WT probe) and 63 ± 0.6 (MT-probe). Any samples that failed to produce a T_m value for either of the SMBs

179 or produced T_m values outside of the range defined for the T_m codes would have been defined as
180 indeterminate and the assay repeated. Using this code definition, we retested our reference RNA samples
181 20 times, and the correct 501/484 allele was detected in each case, achieving an analytic sensitivity and
182 specificity of 100%. These results clearly indicate that the combination of both SMB 501-WT and SMB
183 501-MT probes can specifically detect and differentiate the N501Y variants from the wild type strains with
184 high confidence.

185 **Validation with patient samples.** A total of 76 patient samples, 46 confirmed COVID-19 positive and 30
186 confirmed COVID-19 negative, were tested using the SMB-501 assay. A subset of 45 of these same samples
187 (26 COVID-19 positive and 19 COVID negative) were additionally validated with the SMB-484 assay.
188 None of the COVID-19 negative samples produced any measurable T_m values from either of the assays,
189 yielding a specificity of 100%. Positive samples were selected based on a wide range of N2-Ct values
190 between 16 through 41 based on the Xpert Xpress SARS-CoV-2 assay. As shown in Table 2, 40/45 (89%)
191 of the COVID-19 positive samples produced measurable T_m values for both SMB probes in the SMB-501
192 assay, in at least one of the two replicates. Two samples were identified as indeterminate based on the
193 inability of either the WT or MT probe to generate a measurable T_m and/or due to the presence of a failed
194 internal control. There were also 5 assays from previously positive clinical samples, which generated
195 negative results in that neither probe produced a measurable T_m. All the negative assays had shown an
196 initial Xpert Ct values ≥ 35 . Although, many of the samples with Xpert Ct values as late as 39 could still
197 be detected by our assay, we found that the samples with a Ct ≥ 35 using the Xpert assay, yielded relatively
198 stunted melt peak heights of ≤ 0.3 with the WT-SMB and ≤ 0.1 with MT-SMB similar to that observed when
199 testing 4 GE in our limit of detection studies, which is indicative of very low viral loads in these samples.
200 However, the T_m could still be identified for at least one of the 501 SMB probes in all samples, except the
201 negatives. Overall, 27/45 (60%) of the COVID-19 positive samples had SMB 501-WT and SMB 501-MT
202 T_m values consistent with the WT N501 allele and 11/45 (24.4%) of the samples had T_m values consistent
203 with mutant Y501 allele within ± 1 -standard deviation of our reference standards (Table 1, Fig. 2). Twelve

204 representative WT and mutant samples as predicted by the SMB assay, underwent Sanger sequencing of
205 the PCR products for confirmation of the PCR results. In all cases, the WT or mutant sequences identified
206 by the SMB N501Y assay were confirmed by the sequencing result. Using the confirmed sequencing results
207 as a gold standard, 4/4 of the wild type clinical samples were detected as WT by the SMB N501Y assay,
208 and 8/8 N501Y mutant results were detected as mutant by the assay, demonstrating a clinical sensitivity
209 and specificity of 100%. Similarly, with the SMB-484 assay, 19/26 (73%) of the samples tested were wild
210 type and 4/26 (15.3%) were variants. Out of the 4 variants, 4/4 were sequenced and confirmed to harbor
211 the G>A mutation in the 484th codon, yielding an assay specificity of 100% compared to sequencing. It
212 should be noted that one of the specimens (SMBP-27) contained a E484K mutation but was found to have
213 a WT sequence at codon 501. Considering that the major three VOCs contain either N501Y alone (B.1.1.7)
214 or both N501Y and E484K mutations (B.1.351 and P.1), the presence of this single 484K mutant might
215 indicate that this sample contains the variant of interest B.1.525/B.1.526, which originated in New York
216 City. Thus, the combination of our SMB 501 and SMB-484 assays should help capture most of the variants
217 in circulation. We also observed that the frequency of N501Y and E484K variants increased substantially
218 between the clinical samples obtained in October 2020 and the samples obtained in February and March
219 2021 (Fig. 3).

220 **Discussion.**

221 The emergence of SARS-CoV-2 VOC with the potential for increased transmission, disease severity, and
222 resistance to vaccine induced immunity is of grave concern (14, 28). A simple screening assay to monitor
223 the emergence and spread of these strains may be helpful for implementing public health strategies to
224 counter these and future strains. Our study demonstrates that our assay is simple, rapid, and sensitive and
225 specific for detecting key variant-identifying mutations using a high-throughput PCR assay platform. Thus,
226 this assay has the potential for relatively inexpensive high throughput testing for rapid identification of
227 N501Y, E484K variants. In designing this assay, we took advantage of the fact that the N501Y and E484K
228 mutations are common in the major SARS-CoV-2 variants. Since this mutation also appears to be

229 responsible for the increased infectivity and possibly the other adverse manifestations of these strains (4),
230 assays which detect this mutation may also prove useful to detect any future strain that evolves to have
231 increased transmission potential.

232 Our assay is the first to our knowledge that uses post PCR T_m based analysis to detect and differentiate
233 SARS-CoV-2 variants using SMB probes demonstrated in clinical samples. This assay format has the
234 benefit of producing a measurable T_m result irrespective of whether the SMB probe is fully complementary
235 to its target nucleic acid sequence. Instead of detecting a mutation by either producing or not producing a
236 signal, SMBs detect mutations by producing a T_m shift. Failure to produce a T_m signal indicates an invalid
237 assay rather than the absence of a mutation. The robustness of our assay is further increased by our use of
238 two different SMBs, one complementary to the WT sequence and one complementary to the mutant
239 sequence. The pattern of T_m values or “T_m signature” produced by the combined T_m values of each SMB
240 probe provides an unequivocal identification of a WT or MT sequence. We have also shown that T_m
241 signatures can be used to detect mixtures of mutant and WT sequences and to identify numerous mutations
242 present in an assay’s target region (29). Thus, we expect that our assay should continue to be able to identify
243 N501Y and E484K variants even if additional mutations develop near this primary mutation within the
244 probe-footprint region once the specific T_m signatures of each new genotype are characterized. Our assay
245 is meant to be a screening assay which will identify samples likely to contain SARS-CoV-2 variants of
246 concern. Although in this study, we have proposed to use the combination of two probes per assay for
247 increased accuracy, we expect that most SARS CoV-2 variants can be identified using only the MT-probe
248 alone, and future versions of our assay are likely to use a single SMB to identify mutations that are less
249 critical than N501Y and E484K. We suggest that a useful public health strategy would be to screen COVID-
250 19 positive samples in near real time with our assay, and then to perform genomic sequencing on a subset
251 of screen-positive samples. This sequencing would confirm the presence of the expected variants and in
252 some cases lead to the discovery of new variants. Ongoing sequencing of a subset of all SARS-CoV-2
253 samples will also be required to identify completely novel variants or to investigate the epidemiology and

254 clinical characteristics of variants such as those recently reported in the United States. Fortunately, our
255 assay is easily extensible and additional tests for new key mutations can be added in a modular format to a
256 screening panel when new mutations associated with critical new variants are discovered. In fact, it is our
257 intention to continuously update this assay until our work is superseded by a better approach or much more
258 widespread genome sequencing becomes commonplace. Key updates will also be posted on a preprint
259 journal. In the meantime, we hope that our current test will help increase surveillance and potentially help
260 control the spread of the new emerging variants of concern.

261 **Acknowledgements.** This study was funded by the National Institute of Allergy and Infectious Diseases of
262 the National Institutes of Health under award number R01 AI131617. The following reagent was deposited
263 by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH:
264 Genomic RNA from SARS-Related Coronavirus 2, Isolate USA-WA1/2020, NR-52285. The following
265 reagent was obtained through BEI Resources, NIAID, NIH: Severe Acute Respiratory Syndrome-Related
266 Coronavirus 2, Isolate hCoV-19/England/204820464/20200, NR-54000, contributed by Bassam Hallis. The
267 authors wish to thank all the laboratories that contribute sequence data to the GISAID EpiCoV database. A
268 GISAID acknowledgment table reporting the geographic origin and contributions of genomes analyzed in
269 this study is attached as a supplementary Table 1S.

270 D.A. receives research support and royalty payments from Cepheid, which sells the Xpert Xpress SARS-
271 CoV-2 and Xpert Xpress SARS-CoV-2/Flu/RSV tests., S.C. is an employee of Cepheid and R.J. is a paid
272 consultant for Cepheid.

273

274

275

276 **FIGURE LEGENDS.**

277 **Fig. 1. Analytical limit of detection and T_m values generated by the SMB-501 (A and B) and SMB-**
278 **484 (C and D) assays tested against SARS-CoV-2 RNA. A and C- SARS-CoV-2 wildtype (WT) RNA;**
279 **B- B.1.1.7 mutant (MT) RNA and D- B.351 mutant (MT) RNA at the indicated number of genomic**
280 **equivalents (GEs).**

281
282 **Fig. 2. The effect of target concentration on the melt peak height generated by the SMB-501 (A and**
283 **B) and SMB-484 (C and D) assays tested against SARS-CoV-2 RNA. A and C- SARS-CoV-2 wildtype**
284 **(WT) RNA; B- B.1.1.7 mutant (MT) RNA and D- B.351 mutant (MT) RNA at the indicated number of**
285 **genomic equivalents (GEs).**

286
287 **Fig. 3. Sloppy molecular beacon (SMB) T_m profile of positive clinical nasopharyngeal (NP) samples**
288 **tested using the SMB-501 and SMB-484 T_m assay. T_m signatures consisting of the T_m values for both**
289 **the WT probe (blue) and MT probe (orange) are shown for the SMB-501 assay (A) and the SMB-484 assay**
290 **(B). Ref WT indicates the T_m profile of the reference, WT SARS-CoV-2 strain and Ref MT indicates the**
291 **T_m profile of the reference MT SARS-CoV-2 B.1.1.7 strain (A) and B.351 (B). SMBP1 – SMBP46 indicate**
292 **that T_m profiles of the 46 COVID positive clinical samples tested in this study with SMB-501 assay and**
293 **the 26 COVID positive samples tested by SMB-484 assay. Error bars show +/- one standard deviation.**

294
295 **Fig.4. Prevalence of N501Y variant strains among the tested sample set over time. The proportion of**
296 **N501Y and E484K variants is shown for samples obtained during the periods of October-November (n=9**
297 **tested with SMB-501/n=3 tested with SMB-484), January (n=16/n=12), February (n=15/n=9) and the first**
298 **week of March (n=6/n=2). No samples from December were tested in our study.**

299

300 Table 1. Primers and probes.

Assay	Primer/ Probe	5'	Sequence	3'	Amplicon size (bp)
SMB-501	501-F		ggttttaattgttactttcctttaca		89
	501-R		gaaagtactactactctgtatggttgg		
	501-WT	Quasar 570	CCGCgtt[pdU]ccatcccactaatgctg[pdU]tggttaccacGCGG	BHQ-2	
	501-MT	Quasar 670	CGCGgtt[pdu]ccatcccacttatgctg[pdu]tggttaccacCGCG	BHQ-2	
SMB-484	484-F		ctatcaggccggtagcacac		76
	484-R		gaaaccatatgattgtaaaggaaag		
	484-WT	Quasar 570	CCGCGccttgtaatgggtgtaaaggtttaattgttacGCGCGG	BHQ-2	
	484-MT	Quasar 670	CCGCGccttgtaatgggtgtaaaggtttaattgttacGCGCGG	BHQ-2	

301

302 The lowercase letter indicates the SMB probe region and the uppercase letter indicate the SMB stem region and pdU -C5 Propynyl-deoxyuridine

303 and BHQ indicates “black hole quencher”.

304

305

306 Table 2. Assay and Sanger sequencing results from COVID positive clinical samples.

Samples	Date of 1st test (dd/mm/yy)	PCR Ct*	SMB-501 assay			SMB-484 assay			Confirmation by sequencing†		
			WT probe (Cy3) Tm (°C)	MT probe (Cy5) Tm (°C)	Id	WT probe (Cy3) Tm (°C)	MT probe (Cy5) Tm (°C)	Id	Wild type	N501Y mutant (AAT-TAT)	E484K mutant (GAA-AAA)
WT-Reference			59.8±0.4	58.2±1	WT	64±0.1	58.7±0.4	WT	Yes	No	No
MT-Reference			55.2±0.4	62.2±0.6	MT	59.7±0.5	63±0.6	MT	No	Yes	No
SMBP-1	Oct-Nov 2020	29.1	59.9	58.4	WT	63.9	58.2	WT	Yes	No	No
SMBP-2		34.8	NP	NP	Neg						
SMBP-3		34.5	NP	NP	Neg	64.0	58.7	WT			
SMBP-4		35.4	NP	NP	Neg						
SMBP-5		39.2	59.5	58.2	WT						
SMBP-6		36.0	59.1	58.2	WT				Yes	No	No
SMBP-7		33.7	58.9	58.1	WT	64.0	NP	Ind			
SMBP-8		36.8	59.5	58.2	WT						
SMBP-9		27.9	59.4	58.3	WT						
SMBP-10	Jan 2021	29.4	59.3	58.3	WT	63.8	58.2	WT	Yes	No	No
SMBP-11		39.1	59.9	58.6	WT						
SMBP-12		33.8	59.0	58.2	WT	64.3	58.8	WT	Yes	No	No
SMBP-13		17.7	59.3	58.5	WT	64.2	58.9	WT	Yes	No	No
SMBP-14		21.3	59.4	58.5	WT	64.2	58.8	WT	Yes	No	No
SMBP-15		17.5	59.1	58.3	WT	64.0	58.7	WT	Yes	No	No
SMBP-16		30.0	55.5	62.6	MT	64.2	58.5	WT	No	Yes	No
SMBP-17		41.2	NP	NP	Neg						
SMBP-18		23.2	59.8	58.9	WT	64.0	58.7	WT			
SMBP-19		28.3	59.3	58.1	WT	63.8	58.2	WT	Yes	No	No
SMBP-20		17.1	59.2	58.3	WT	64.0	58.8	WT	Yes	No	No
SMBP-21		16.4	59.2	58.4	WT	64.2	58.9	WT	Yes	No	No
SMBP-22		18.2	58.9	58.1	WT				Yes	No	No
SMBP-23		21.1	58.9	58.1	WT	64.1	58.6	WT	Yes	No	No
SMBP-24		39.0	59.5	58.2	WT						
SMBP-25		28.4	54.5	61.6	MT	64.1	NP	Ind	No	Yes	No
SMBP-26	Feb 2021	27.8	54.5	61.6	MT	63.9	58.3	NP	No	Yes	No

SMBP-27		33.5	59.3	58.9	WT	60.1	63.0	MT	Yes	No	Yes
SMBP-28		38.3	59.7	58.5	WT	64.1	NP	Ind	ND	ND	ND
SMBP-29		18.1	58.9	58.1	WT	64.1	58.8	WT	Yes	No	No
SMBP-30		27.8	59.2	58.2	WT						
SMBP-31 ^a		17.6	55.1	61.9	MT	60.4	63.3	MT	No	Yes	Yes
SMBP-32 ^a		17.4	55.1	61.9	MT	64.0	58.7	WT	No	Yes	No
SMBP-33		32.8	55.0	62.1	MT						
SMBP-34		25.2	55.5	62.7	MT	60.2	63.3	MT	No	Yes	Yes
SMBP-35		18.4	55.6	62.5	MT	60.5	63.4	MT	No	Yes	Yes
SMBP-36		18.8	54.9	61.9	MT				No	Yes	No
SMBP-37		28.4	54.9	62.2	MT						
SMBP-38		16.4	59.8	58.5	WT	64.1	58.6	WT			
SMBP-39		32.2	NP	NP	Neg						
SMBP-40		32.3	58.9	57.8	WT				Yes	No	No
SMBP-41	March 2021	32.6	55.4	62.6	MT	63.9	58.3	WT	No	Yes	No
SMBP-42		36.8	59.7	58.4	WT						
SMBP-43		30.1	59.8	58.9	WT				Yes	No	No
SMBP-44		33.3	NP	NP	Inv						
SMBP-45		34.6	NP	61.3	Ind						
SMBP-46		23.3	59.2	58.285	WT	64.0	58.6	WT	Yes	No	No

307


308 IC-internal control; WT-wildtype; MT-Mutant; NP- No Tm peak; Neg-Negative; ND- not Inv-Invalid; Ind-Indeterminate.

309 *Xpert Xpress SARS-CoV-2 or Xpert Xpress SARS-CoV-2/Flu/RSV tests

310 †Representative strains were sequenced. ^asequencing was repeated twice to confirm the identified mutations.

311 Blocked grey cells- Corresponding samples that are not tested by the SMB-484 assay or sequencing.

312



313


314

315 **Fig. 1.**

316

317

318




319

320


321 **Fig. 2.**

322



323

324 **Fig. 3.**



325

326 **Fig.4.**